

Vita Fedele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3752865/publications.pdf>

Version: 2024-02-01

8
papers

231
citations

1307594
7
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

635
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 638360.	2.8	42
2	Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. <i>Npj Breast Cancer</i> , 2021, 7, 118.	5.2	3
3	A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal/gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093788.	3.2	28
4	HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. <i>Cancers</i> , 2020, 12, 3299.	3.7	14
5	A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094796.	3.2	9
6	Permissive State of EMT: The Role of Immune Cell Compartment. <i>Frontiers in Oncology</i> , 2020, 10, 587.	2.8	19
7	Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4661-4669.	7.0	18
8	Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. <i>Nature Communications</i> , 2018, 9, 1028.	12.8	98